DocWire News Editors

DocwireNews

There are limited data on patient preferences for biologic agents for the treatment of asthma. Researchers assessed patient and physician perceptions on biologic agents for the treatment of severe asthma. The results of the study were presented at the AMCP Annual Meeting during a poster session titled &ldquo;Patient and Physician Preferences for Attributes of Biologic Medications for Severe Asthma.&rdquo;This cross-sectional mixed-methods study used qualitative interviews and direct rating and preference elicitation questions. The study is ongoing, and the researchers plan to enroll up to 50 patients with severe, uncontrolled asthma and 25 board-certified pulmonologists and allergists who have previously prescribed these agents for severe asthma.Participants provided input on relevant attributes and barriers to these agents in an open-ended, semi-structured telephone interview. They rated the importance of the following:<ul>
<li>Mode of administration</li>
<li>Dosing frequency</li>
<li>Number of injections</li>
<li>Time required for administration</li>
<li>Time to onset of effect</li>
<li>Frequency of treatment</li>
<li>Administration setting</li>
</ul>As of the current reporting, nine patient interviews were complete. Time to onset of effect and out-of-pocket cost were most consistently reported by patients as important. The top three attributes of treatment were out-of-pocket cost, onset of effect, and frequency of administration.Patients consistently preferred biologics that were administered:<ul>
<li>More than one month apart versus less than one month apart</li>
<li>Every eight weeks versus every two or four weeks</li>
<li>Subcutaneously versus intravenously</li>
</ul>Barriers to care included high out-of-pocket costs and the large time commitment (e.g., ordering the medication, travel to the site, and clinic time for receiving the medication).&ldquo;The insights from patients can help inform the decision-making process for biologic treatment for severe asthma,&rdquo; the researchers concluded.The study was sponsored by AstraZeneca.Gelhorn H, Ross M, Balantac Z, Cutts K, Buachie R, Fox K, Ambrose C, Stone B. Patient and Physician Preferences for Attributes of Biologic Medications for Severe Asthma. Abstract J6. Presented at the AMCP Managed Care &amp; Specialty Pharmacy Annual Meeting, April 23-26; Boston, MA.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Patient Treatment Preference for Biologic Asthma Agents

AMCP 2018

There are limited data on patient preferences for biologic agents for the treatment of asthma. Researchers assessed patient and physician perceptions on biologic agents for ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe